Maureen Hillenmeyer

Maureen Hillenmeyer is the founder and CEO of Hexagon Bio, a Menlo Park drug-discovery company that mines the genomes of fungi for hidden small molecules and engineers yeast to brew them into potential medicines. A former competitive swimmer turned computational biologist, she holds a PhD in biomedical informatics from Stanford and built the company out of a Stanford research program she led, raising more than $270 million to turn DNA sequence data into cancer and infectious-disease therapeutics.